V V Tuliani1, E A O'Rear. 1. Smith Kline Beecham Pharmaceuticals, Prussia, Pennsylvania 19406, USA.
Abstract
PURPOSE: A model for calculating the circulatory concentrations of fibrinolytic species is proposed and the findings are compared to reported values where available. METHODS: The model uses a CSTR analysis with fourth order Runge-Kutta solution of the differential equations to determine concentration profiles of key fibrinolytic species as a function of time during fibrinolytic therapy. Concentrations of the species are also determined for various dosage regimens of streptokinase and plasminogen. RESULTS: Data calculated by the model is in agreement with general experimental trends determined in vitro and in vivo. CONCLUSIONS: The proposed model can be used to predict concentration profiles of key fibrinolytic species during administration of streptokinase.
PURPOSE: A model for calculating the circulatory concentrations of fibrinolytic species is proposed and the findings are compared to reported values where available. METHODS: The model uses a CSTR analysis with fourth order Runge-Kutta solution of the differential equations to determine concentration profiles of key fibrinolytic species as a function of time during fibrinolytic therapy. Concentrations of the species are also determined for various dosage regimens of streptokinase and plasminogen. RESULTS: Data calculated by the model is in agreement with general experimental trends determined in vitro and in vivo. CONCLUSIONS: The proposed model can be used to predict concentration profiles of key fibrinolytic species during administration of streptokinase.
Authors: J D Gemmill; K J Hogg; J M Burns; A P Rae; F G Dunn; R Fears; H Ferres; R Standring; H Greenwood; D Pierce Journal: Br J Clin Pharmacol Date: 1991-02 Impact factor: 4.335